Summary of Study ST001680
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001079. The data can be accessed directly via it's Project DOI: 10.21228/M8797T This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST001680 |
Study Title | Metabolome of NAFLD in high fat diet mouse model |
Study Summary | We investigated the effects of a RAR beta 2 agonist, AC261066, on the hepatic metabolites changed in high fat fed NAFLD mouse model. We suggest that AC261066 has potential therapeutic relevance for the prevention/treatment of NAFLD and NASH. |
Institute | Weill Cornell Medicine |
Last Name | Gudas |
First Name | Lorraine |
Address | 1300 York Ave |
chl2029@med.cornell.edu | |
Phone | 646-3094389 |
Submit Date | 2021-01-27 |
Raw Data Available | Yes |
Raw Data File Type(s) | d |
Analysis Type Detail | LC-MS |
Release Date | 2022-01-27 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001079 |
Project DOI: | doi: 10.21228/M8797T |
Project Title: | Metabolome of NAFLD in high fat diet mouse model |
Project Summary: | We investigated the effects of a RAR beta 2 agonist, AC261066, on the hepatic metabolites changed in high fat fed NAFLD mouse model. We suggest that AC261066 has potential therapeutic relevance for the prevention/treatment of NAFLD and NASH. |
Institute: | Weill Cornell Medical College |
Laboratory: | Lorraine Gudas |
Last Name: | Lorraine |
First Name: | Gudas |
Address: | 1300 York Ave, New York, NY, 10065, USA |
Email: | chl2029@med.cornell.edu |
Phone: | 646-3094389 |
Subject:
Subject ID: | SU001757 |
Subject Type: | Mammal |
Subject Species: | Mus musculus |
Taxonomy ID: | 10090 |
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
mb_sample_id | local_sample_id | Treatment |
---|---|---|
SA154567 | anp-neg-Control-217 | chow |
SA154568 | C18-neg-Control-217b | chow |
SA154569 | C18-neg-Control-316b | chow |
SA154570 | anp-pos-Control-417b | chow |
SA154571 | C18-neg-Control-316 | chow |
SA154572 | anp-pos-Control-317b | chow |
SA154573 | anp-pos-Control-316 | chow |
SA154574 | anp-pos-Control-316b | chow |
SA154575 | anp-pos-Control-317 | chow |
SA154576 | C18-neg-Control-317 | chow |
SA154577 | anp-pos-Control-417 | chow |
SA154578 | C18-neg-Control-417 | chow |
SA154579 | C18-pos-Control-317 | chow |
SA154580 | C18-pos-Control-317b | chow |
SA154581 | C18-pos-Control-417 | chow |
SA154582 | C18-pos-Control-417b | chow |
SA154583 | C18-pos-Control-316b | chow |
SA154584 | C18-pos-Control-316 | chow |
SA154585 | anp-pos-Control-217b | chow |
SA154586 | C18-neg-Control-417b | chow |
SA154587 | C18-pos-Control-217 | chow |
SA154588 | C18-pos-Control-217b | chow |
SA154589 | C18-neg-Control-317b | chow |
SA154590 | C18-neg-Control-217 | chow |
SA154591 | anp-neg-Control-317 | chow |
SA154592 | anp-neg-Control-316b | chow |
SA154593 | anp-neg-Control-417 | chow |
SA154594 | anp-neg-Control-417b | chow |
SA154595 | anp-pos-Control-217 | chow |
SA154596 | anp-neg-Control-316 | chow |
SA154597 | anp-neg-Control-317b | chow |
SA154598 | anp-neg-Control-217b | chow |
SA154599 | C18-neg-HFD-316 | high fat diet |
SA154600 | C18-neg-HFD-416 | high fat diet |
SA154601 | C18-neg-HFD-417 | high fat diet |
SA154602 | C18-neg-HFD-217b | high fat diet |
SA154603 | C18-neg-HFD-217 | high fat diet |
SA154604 | anp-neg-HFD-316 | high fat diet |
SA154605 | anp-neg-HFD-217b | high fat diet |
SA154606 | C18-neg-HFD-216 | high fat diet |
SA154607 | C18-neg-HFD-4217 | high fat diet |
SA154608 | anp-neg-HFD-217 | high fat diet |
SA154609 | C18-pos-HFD-317 | high fat diet |
SA154610 | C18-pos-HFD-316 | high fat diet |
SA154611 | C18-pos-HFD-216 | high fat diet |
SA154612 | C18-pos-HFD-217 | high fat diet |
SA154613 | C18-pos-HFD-416 | high fat diet |
SA154614 | anp-neg-HFD-317 | high fat diet |
SA154615 | anp-neg-HFD-216 | high fat diet |
SA154616 | C18-pos-HFD-4217 | high fat diet |
SA154617 | C18-pos-HFD-417 | high fat diet |
SA154618 | C18-pos-HFD-217b | high fat diet |
SA154619 | C18-neg-HFD-317 | high fat diet |
SA154620 | anp-pos-HFD-317 | high fat diet |
SA154621 | anp-pos-HFD-416 | high fat diet |
SA154622 | anp-pos-HFD-417 | high fat diet |
SA154623 | anp-pos-HFD-316 | high fat diet |
SA154624 | anp-pos-HFD-217b | high fat diet |
SA154625 | anp-pos-HFD-216 | high fat diet |
SA154626 | anp-pos-HFD-217 | high fat diet |
SA154627 | anp-neg-HFD-416 | high fat diet |
SA154628 | anp-pos-HFD-4217 | high fat diet |
SA154629 | anp-neg-HFD-417 | high fat diet |
SA154630 | anp-neg-HFD-4217 | high fat diet |
SA154631 | anp-pos-HFD-Drug-116 | high fat diet+AC261066 |
SA154632 | anp-neg-HFD-Drug-116 | high fat diet+AC261066 |
SA154633 | C18-pos-HFD-Drug-116 | high fat diet+AC261066 |
SA154634 | C18-neg-HFD-Drug-116 | high fat diet+AC261066 |
SA154635 | C18-pos-HFD-Drug-116b | high fat diet+AC261067 |
SA154636 | anp-pos-HFD-Drug-116b | high fat diet+AC261067 |
SA154637 | anp-neg-HFD-Drug-116b | high fat diet+AC261067 |
SA154638 | C18-neg-HFD-Drug-116b | high fat diet+AC261067 |
SA154639 | C18-neg-HFD-Drug-217 | high fat diet+AC261068 |
SA154640 | anp-neg-HFD-Drug-217 | high fat diet+AC261068 |
SA154641 | C18-pos-HFD-Drug-217 | high fat diet+AC261068 |
SA154642 | anp-pos-HFD-Drug-217 | high fat diet+AC261068 |
SA154643 | C18-neg-HFD-Drug-217b | high fat diet+AC261069 |
SA154644 | C18-pos-HFD-Drug-217b | high fat diet+AC261069 |
SA154645 | anp-neg-HFD-Drug-217b | high fat diet+AC261069 |
SA154646 | anp-pos-HFD-Drug-217b | high fat diet+AC261069 |
SA154647 | C18-pos-HFD-Drug-316 | high fat diet+AC261070 |
SA154648 | anp-pos-HFD-Drug-316 | high fat diet+AC261070 |
SA154649 | anp-neg-HFD-Drug-316 | high fat diet+AC261070 |
SA154650 | C18-neg-HFD-Drug-316 | high fat diet+AC261070 |
SA154651 | C18-pos-HFD-Drug-316b | high fat diet+AC261071 |
SA154652 | C18-neg-HFD-Drug-316b | high fat diet+AC261071 |
SA154653 | anp-pos-HFD-Drug-316b | high fat diet+AC261071 |
SA154654 | anp-neg-HFD-Drug-316b | high fat diet+AC261071 |
SA154655 | C18-pos-HFD-Drug-417 | high fat diet+AC261072 |
SA154656 | anp-neg-HFD-Drug-417 | high fat diet+AC261072 |
SA154657 | anp-pos-HFD-Drug-417 | high fat diet+AC261072 |
SA154658 | C18-neg-HFD-Drug-417 | high fat diet+AC261072 |
SA154659 | anp-neg-HFD-Drug-417b | high fat diet+AC261073 |
SA154660 | C18-pos-HFD-Drug-417b | high fat diet+AC261073 |
SA154661 | C18-neg-HFD-Drug-417b | high fat diet+AC261073 |
SA154662 | anp-pos-HFD-Drug-417b | high fat diet+AC261073 |
Showing results 1 to 96 of 96 |
Collection:
Collection ID: | CO001750 |
Collection Summary: | At the termination of the treatments, after fasting overnight mice were sacrificed by cervical dislocation and liver samples were harvested for analysis. |
Sample Type: | Liver |
Treatment:
Treatment ID: | TR001770 |
Treatment Summary: | Wild-type (wt) male C57BL/6 mice (6-7 weeks old) were maintained on either a standard laboratory chow (Con) diet with 13 % kcal fat (diet no. 5053, Pico Diet, St. Louis, MO), or a high fat diet (HFD) with 60% kcal from fat (diet no. 58125, Test Diet, Inc., St. Louis, MO) for 4 months. Two months after the start of the HFD, the mice were further split into three groups for 2 months to remain on (i) chow plus drinking water with 0.2 % DMSO; (ii) HFD plus drinking water containing 0.2 % DMSO; or (iii) HFD plus 3 mg AC261066 per 100 ml drinking water with 0.2 % DMSO. |
Sample Preparation:
Sampleprep ID: | SP001763 |
Sampleprep Summary: | The snap frozen liver samples were incubated with 600 µL of 3 mM monobrombimane (MBB) in CH3OH:H2O (80:20) at -20°C for 2 h, followed by 1 h incubation at 0°C. This initial incubation was followed by tissue disruption using stainless steel beads in a TissueLyser (Qiagen) and an additional 30 min at -20°C. Extracts were centrifuged for 15 min at 13000 rpm to pellet insoluble material and supernatants were transferred to clean tubes. This extraction was repeated two additional times and all three supernatants were dried in a speed-vac (Savant) and stored at −80 °C until analysis. |
Combined analysis:
Analysis ID | AN002738 | AN002739 | AN002740 | AN002741 |
---|---|---|---|---|
Analysis type | MS | MS | MS | MS |
Chromatography type | Normal phase | Normal phase | Reversed phase | Reversed phase |
Chromatography system | Agilent 1290 Infinity II | Agilent 1290 Infinity II | Agilent 1290 Infinity II | Agilent 1290 Infinity II |
Column | Cogent Diamond Hydride (150 × 2.1mm,3.5um) | Cogent Diamond Hydride (150 × 2.1mm,3.5um) | Agilent Zorbax RRHD SB-C18 (100 x 2.1mm,1.8um) | Agilent Zorbax RRHD SB-C18 (100 x 2.1mm,1.8um) |
MS Type | ESI | ESI | ESI | ESI |
MS instrument type | QTOF | QTOF | QTOF | QTOF |
MS instrument name | Agilent 6550 QTOF | Agilent 6550 QTOF | Agilent 6550 QTOF | Agilent 6550 QTOF |
Ion Mode | POSITIVE | NEGATIVE | POSITIVE | NEGATIVE |
Units | abundance | abundance | abundance | abundance |
Chromatography:
Chromatography ID: | CH002024 |
Chromatography Summary: | The mobile phase for ANP separation consisted of 6 mM EDTA and 0.025% acetic acid in isopropanol:H2O (50:50) (solvent A) and 6 mM EDTA and 5mM ammonium acetate in CH3CN: H2O (90:10) (solvent B). Gradient steps were applied as follows: 0–1 min, 99% B; 1–15 min, to 20% B; 15.1–29 min, 0% B; 29.01-35 min, 99% B. |
Instrument Name: | Agilent 1290 Infinity II |
Column Name: | Cogent Diamond Hydride (150 × 2.1mm,3.5um) |
Chromatography Type: | Normal phase |
Chromatography ID: | CH002025 |
Chromatography Summary: | The mobile phase for RP separation consisted of 1 mM ammonium formate and 0.1% formic acid in H2O (solvent A) and 0.1% formic acid in CH3CN (solvent B). The gradient was as follows: 0–2 min, 1% B; 2– 20 min, to 50% B; 20–25 min, to 85% B; 25-30 min, to 99% B; 30.01-36 min, 1% B. |
Instrument Name: | Agilent 1290 Infinity II |
Column Name: | Agilent Zorbax RRHD SB-C18 (100 x 2.1mm,1.8um) |
Flow Gradient: | 0-2 min, 1% B; 2- 20 min, to 50% B; 20-25 min, to 85% B; 25-30 min, to 99% B; 30.01-36 min, 1% B |
Solvent A: | 100% water; 0.1% formic acid; 1 mM ammonium formate |
Solvent B: | 100% acetonitrile; 0.1% formic acid |
Chromatography Type: | Reversed phase |
MS:
MS ID: | MS002535 |
Analysis ID: | AN002738 |
Instrument Name: | Agilent 6550 QTOF |
Instrument Type: | QTOF |
MS Type: | ESI |
MS Comments: | Agilent MassHunter Workstation |
Ion Mode: | POSITIVE |
MS ID: | MS002536 |
Analysis ID: | AN002739 |
Instrument Name: | Agilent 6550 QTOF |
Instrument Type: | QTOF |
MS Type: | ESI |
MS Comments: | Agilent MassHunter Workstation |
Ion Mode: | NEGATIVE |
MS ID: | MS002537 |
Analysis ID: | AN002740 |
Instrument Name: | Agilent 6550 QTOF |
Instrument Type: | QTOF |
MS Type: | ESI |
MS Comments: | Agilent MassHunter Workstation |
Ion Mode: | POSITIVE |
MS ID: | MS002538 |
Analysis ID: | AN002741 |
Instrument Name: | Agilent 6550 QTOF |
Instrument Type: | QTOF |
MS Type: | ESI |
MS Comments: | Agilent MassHunter Workstation |
Ion Mode: | NEGATIVE |